Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison
Т. 15, №1 (57)
Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score <1%: pooled analysis of outcomes after five years of follow-up
Т. 15, №1 (57)
Thromboprophylaxis with original enoxaparin in oncology patients
Т. 15, №1 (57)